US5270344A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating a systemic disorder using trioxolane and diperoxide compounds
Assignee: WESTERN HOLDING Co Ltd
•
Filing: 1992-02-24
•
Granted: 1993-12-14
•
Expires: 2012-02-24
Abstract
Abstract The present invention provides a method of medical treatment for systemic disorders and oral pharyngeal conditions in a mammal. In this method, a pharmacologically effective amount for treatment of the disorder or condition of a trioxolane or a diperoxide of an unsaturated hydrocarbon, such as a terpene or non-terpene, is applied to the mammal. The invention also provides pharmaceutical compositions for use in these methods.
Inventors
- 👤 Stephen Herman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 16:23
CPC Classifications
C; C07; C07D; C07D323/00; C07D323/02; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61L; A61L2/00; A61L2/16; A61L2/18; A61L2103/00; A61L2103/05; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
96 words
A method of medical treatment for a systemic disorder in a mammal, comprising the application to the intestine of said mammal of a pharmacologically effective amount for treatment of said condition of a trioxolane or a diperoxide derivative of an unsaturated hydrocarbon in a form which releases active ingredient in the intestine for intestinal absorption, wherein said derivative is prepared by dissolving said hydrocarbon in a nonpolar solvent and passing ozone through the dissolved hydrocarbon under conditions that provide for intimate contact between said hydrocarbon and said ozone at a temperature of 35° C. or below.
Claim 2
Independent Claim
96 words
A method of medical treatment for a systemic disorder in a mammal, comprising the application to the intestine of said mammal of a pharmacologically effective amount for treatment of said condition of a trioxolane or a diperoxide derivative of an unsaturated hydrocarbon in a form which releases active ingredient in the intestine for intestinal absorption, wherein said derivative is prepared by dissolving said hydrocarbon in a nonpolar solvent and passing ozone through the dissolved hydrocarbon under conditions that provide for intimate contact between said hydrocarbon and said ozone at a temperature of 35° C. or below.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein said disorder comprises an intestinal infection.
Claim 4
Dependent Claim
11 words
The method of claim 1, wherein said hydrocarbon comprises a terpene.
Claim 5
Dependent Claim
11 words
The method of claim 1, wherein said hydrocarbon comprises a non-terpene.
Claim 6
Dependent Claim
20 words
The method of claim 1, wherein said form is selected from the group consisting of gel caps, capsules and lozenges.
Claim 7
Dependent Claim
29 words
The method of claim 2, wherein said intestinal infection is an infection of a species selected from the group consisting of Salmonella spp., Shigella spp. and enteropathogenic/enterotoxigenic Escherichia coli.
Claim 8
Dependent Claim
29 words
The method of claim 1, wherein said infection is an infection of a species selected from the group consisting of Neisseria gonorrhoea, Candida spp., Candida albicans and Pseudomonas spp.
Claim 9
Dependent Claim
27 words
The method of claim 1, wherein said infection is an infection of a species selected from the group consisting of Klebsiella spp., Staphylococcus aureus and Staphylococcus epidermis.
Claim 10
Dependent Claim
32 words
The method of claim 1, wherein said infection comprises a fungal infection of a species selected from the group consisting of Trichophyton violaceum, Trichophyton canis, Crytococcus spp., Phialophora spp., and Penicillium spp.
Claim 11
Dependent Claim
27 words
The method of claim 1, wherein said infection comprises an infection of an organism selected from the group consisting of Leishmania donovani, Proteus, Achromobacter and E. coli.
Claim 12
Dependent Claim
26 words
The method of claim 1, wherein the application comprises application of from 0.2 mg/kg body weight to 400 mg/kg body weight of said derivative per day.
Claim 13
Dependent Claim
26 words
The method of claim 11, wherein the application comprises application of from 2 mg/kg body weight to 200 mg/kg body weight of said derivative per day.
References Cited (Backward Citations)
US1910564A
Cited
US925590A
Cited
GB191227371A
Cited
US1210949A
Cited
US2083572A
Cited
US2243053A
Cited
US2356062A
Cited
US2750411A
Cited
GB787748A
Cited
US3360472A
Cited
US3504038A
Cited
US4163800A
Cited
US4451480A
Cited
US4591602A
Cited
US4632980A
Cited
US4632980B1
Cited
US4816478A
Cited
WO1989012626A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-12-13 | 1997-06-14 | 1997-12-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-12-13 | 2001-06-14 | 2001-12-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-12-13 | 2005-06-14 | 2005-12-14 | $7700.00 | Window Closed / Lapsed |